

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: The Yield Growth Corp. (the “**Issuer**”).

Trading Symbol: BOSS

Number of Outstanding Listed Securities: 116,248,845 common shares (plus 47,891,869 common shares reserved for issuance in the form of 32,828,041 warrants and 15,063,828 options)

Date: March 1, 2020

Report on Business

1. **Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

On February 4, 2020, the Issuer’s subsidiary, Flourish Mushroom Labs Inc. (“**Flourish**”) appointed leading patent lawyer, Charles Boulakia to its advisory board. Mr. Boulakia has over 20 years of experience in the preparation and prosecution of patent applications in a variety of industries including: biotechnology, chemistry, biofuel, oil and gas and pharmaceuticals.

On February 6, 2020, the Issuer’s subsidiary Flourish announced that it completed an acquisition of approximately 18% of the outstanding shares of Translational Life Sciences Inc.

On February 13, 2020, the Issuer’s subsidiary Flourish announced that it signed a non-binding letter of intent with Kingdom Brands Management Inc. (“**Kingdom**”) on February 12, 2020.

On February 20, 2020, the Issuer’s subsidiary Flourish announced that it acquired technology rights from the Issuer and filed a U.S. provisional patent from the invention of a method of manufacture for a mushroom extract that may be used in a variety of therapeutic and pharmaceutical formulations.

On February 25, 2020, the Issuer announced that it is initiating stability testing and commercialization for a new product, an all-natural hand sanitizer that uses natural ingredients to fight against germs and bacteria.

On February 27, 2020, the Issuer’s subsidiary Flourish announced it has completed product development for Ayurvedic mushroom coffees and Ayurvedic mushroom botanical shots for smoothies.

2. **Provide a general overview and discussion of the activities of management.**
Please see Item 1 above.
3. **Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.**
Please see Item 1 above.
4. **Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.**
None.
5. **Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.**
Please see Item 1 above.
6. **Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.**
None.
7. **Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.**
Please see Item 1 above.
8. **Describe the acquisition of new customers or loss of customers.**
Please see Item 1 above.
9. **Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.**
Please see Item 1 above.
10. **Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.**
None.
11. **Report on any labour disputes and resolutions of those disputes if applicable.**
None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
Common Shares	280,666	February 4, 2020: 280,666 common shares issued at a price of \$0.195 per share pursuant to a warrant exercise	Net proceeds of \$54,729.87 to be used for general working capital
Stock Options	100,000	February 5, 2020: 100,000 stock options granted to an employee at an exercise price of \$0.28 per common share for a maximum period of 5 years (or earlier in accordance with the Issuer's stock option plan)	Not applicable
Special Warrants	226,071	February 6, 2020: 226,071 special warrants issued pursuant to a private placement at a price of \$0.28 per special warrant. Each special warrant is exercisable without further payment into one unit of the Issuer pursuant to the terms and conditions of the prospectus supplement filed on February 11, 2020	Net proceeds of \$63,300. to be used as set out in the Prospectus Supplement.
Common Shares	313,000	February 10, 2020: 313,000 common shares issued at a price of \$0.25 per share pursuant to a warrant exercise	Net proceeds of \$78,250 to be used for general working capital

Units	226,071	February 14, 2020: 226,071 units issued pursuant to the conversion of the special warrants issued on February 6, 2020. Each unit consists of one common share and one common share purchase warrant exercisable at \$0.29 until February 6, 2021.	
Special Warrants	1,363,300	February 14, 2020: 1,363,300 special warrants issued pursuant to a private placement at a price of \$0.20 per special warrant. Each special warrant is exercisable without further payment into one unit of the Issuer pursuant to the terms and conditions of the prospectus supplement filed on February 20, 2020	Net proceeds of \$272,660 to be used as set out in the Prospectus Supplement.
Common Shares	20,000	February 25, 2020: 20,000 common shares issued at a price of \$0.10 per share pursuant to an option exercise	Net proceeds of \$2,000 to be used for general working capital
Units	1,363,300	February 25, 2020: 1,363,300 units issued pursuant to the conversion of the 1,363,300 special warrants issued on February 14, 2020. Each unit consists of one common share and one common share purchase warrant exercisable at \$0.26 until June 14, 2020.	

(1) State aggregate proceeds and intended allocation of proceeds.

15. **Provide details of any loans to or by Related Persons.**

None.

16. **Provide details of any changes in directors, officers or committee members.**

None.

17. **Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.**

On October 17, 2018, The Cannabis Act came into force in Canada and recreational cannabis is now available to legal adults (aged 18 or 19 depending on the province or territory) for purchase, growth, or use in limited quantities. On October 17, 2019, additional legislation came into force in Canada allowing and regulating the use and sale of Cannabis topical and edible products.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated March 1, 2020.

Penny White
Name of Director or Senior Officer

"Penny White"
Signature

Chief Executive Officer and
President
Official Capacity

Issuer Details Name of Issuer The Yield Growth Corp.	For Month End February 2020	Date of Report YY/MM/DD 20/03/01
Issuer Address Suite 200, 1238 Homer Street		
City/Province/Postal Code Vancouver, British Columbia V6B 2Y5	Issuer Fax No. N/A	Issuer Telephone No. 833.514.2677
Contact Name Penny White	Contact Position President, CEO, and Director	Contact Telephone No. 833.514.2677
Contact Email Address penny@yieldgrowth.com	Web Site Address www.yieldgrowth.com	